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Abstract
Staphylococcus aureus is a major cause of mastitis in ruminants. In ewe mastitis, symptoms range from subclinical
to gangrenous mastitis. S. aureus factors or host-factors contributing to the different outcomes are not completely
elucidated. In this study, experimental mastitis was induced on primiparous ewes using two S. aureus strains,
isolated from gangrenous (strain O11) or subclinical (strain O46) mastitis. Strains induced drastically distinct clinical
symptoms when tested in ewe and mice experimental mastitis. Notably, they reproduced mild (O46) or severe
(O11) mastitis in ewes. Ewe sera were used to identify staphylococcal immunoreactive proteins commonly or
differentially produced during infections of variable severity and to define core and accessory seroproteomes. Such
SERological Proteome Analysis (SERPA) allowed the identification of 89 immunoreactive proteins, of which only 52
(58.4%) were previously identified as immunogenic proteins in other staphylococcal infections. Among the 89
proteins identified, 74 appear to constitute the core seroproteome. Among the 15 remaining proteins defining the
accessory seroproteome, 12 were specific for strain O11, 3 were specific for O46. Distribution of one protein
specific for each mastitis severity was investigated in ten other strains isolated from subclinical or clinical mastitis.
We report here for the first time the identification of staphylococcal immunogenic proteins common or specific to
S. aureus strains responsible for mild or severe mastitis. These findings open avenues in S. aureus mastitis studies as
some of these proteins, expressed in vivo, are likely to account for the success of S. aureus as a pathogen of the
ruminant mammary gland.
Introduction
Mastitis is the first cause of economical loss in milk
production worldwide [1] and is a major concern in
milk transformation [2]. The problem is however cur-
rently hard to tackle for mastitis in dairy cows, sheep
and goats. Especially, S. aureus mastitis is typically
refractory to antibiotic treatment. Prophylactic mea-
sures, including the development of an effective vaccine,
have so far proven unsuccessful for the control of the
disease. S. aureus is well-known to produce a large vari-
ety of virulence factors (including numerous proteins
like toxins or adhesins). Consequently, it induces a large
panel of infections, and the clinical acuteness of each
infection type may also be variable. For example,
S. aureus mastitis in dairy sheep ranges from subclinical
mastitis to lethal gangrenous mastitis. Such variability
relies on staphylococcal virulence factors as well as host
factors. Until now, no study has been performed
to identify the transcripts and proteins commonly or
specifically produced in vivo by S. aureus strains during
mastitis. To obtain such information using direct tran-
scriptomic or proteomic approaches upon S. aureus
samples collected within the infection site stumbles
on technical bottlenecks such as the low amounts of
S. aureus cells and the difficulty to localize the infection
site within the udder.
Serological proteome analysis (SERPA) is a promising
technique that can be used to shed light on the host’s
immune response to staphylococcal infection. This tech-
nique was used to mine new antigen candidates for vac-
cine development in human infections [3]. SERPA has
also been used to identify proteins produced in vivo,
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shotgun sequencing, SERPA is a powerful tool to iden-
tify immunoreactive proteins produced by S. aureus dur-
ing the infection [5].
Genotyping studies indicated that S. aureus strains
isolated from dairy sheep farms in the south east of
France were clonally related and are predominantly
represented by a single pulse-field gel electrophoresis
(PFGE) type OV/OV’ [6,7]. Such close phylogenetic rela-
tionship was recently confirmed at the global scale using
Multi Locus Sequence Typing and comparative genome
hybridization [8,9]. Among strains in this OV/OV’ PFGE
profile, one was isolated from subclinical mastitis (O46)
and another one from gangrenous mastitis (O11). Few
genetic differences were identified [10] and their role in
the development of mastitis with such different severity
has not yet been determined. Moreover identification of
the proteins produced by S. aureus in mastitis with dif-
ferent severity is an important step to better understand
the host-pathogen interactions and to provide targets
for the development of efficient prevention or treatment
strategies against mastitis. Therefore, we applied SERPA
to identify proteins that are produced by both S. aureus
strains O11 and O46 (core seroproteome) and the ones
specifically produced by each strain (“accessory”
seroproteome).
Materials and methods
Bacterial strains, growth conditions and preparation of
protein samples
S. aureus strains used in this study are presented in Table
1. S. aureus O46 was isolated from a case of ovine subcli-
nical mastitis and O11 from a gangrenous lethal mastitis
[10]. Genetic and genotypic background of S. aureus O46
and O11 are well-documented. They share the same pul-
sotype (OV/OV’) and are representative of the major
lineage found associated to ewe mastitis in south east of
France [6,7]. Growth conditions and preparation of pro-
tein extracts were as described in Le Maréchal et al. 2009
[11]. Briefly, overnight cultures in BHI were diluted
1:1000 in fresh RPMI 1640 medium (Sigma, Saint Quen-
tin Fallavier, France). RPMI was extemporaneously
depleted of iron (and hereafter referred to as iron-
depleted RPMI) by adding deferoxamine (0.15 mM)
(Sigma). Growth conditions in which there is restriction
in the bioavailability of iron can indeed lead to an
increase of the expression of virulence factors which are
normally expressed in vivo [12]. S. aureus strains were
grown in 500 mL flasks under agitation (150 rpm) at
37 °C (a flask-to-broth volumetric ratio of 5), for aerobic
conditions, or in falcon tubes (50 mL) completely filled
with medium and incubated at 37 °C without agitation
for anaerobic conditions. Protein samples for superna-
tant, cell wall or total fraction were prepared exactly as
previously described [11].
Genome sequencing of O11 and O46 strains
To facilitate the analysis of SERPA results, the genome of
the two strains used in experimental infection was fully
sequenced using the Solexa technology (P Mayer, L Fari-
nelli, and E Kawashima, 1997. Patent application WO98/
44151) according to the manufacturer’sp r o t o c o l( I l l u -
mina, San Diego, CA, USA). Briefly, genomic DNA was
physically fragmented by nebulization into 50- to 500-bp
fragments. After end repair and ligation of the bar-coded
paired-end adaptors, the products were purified on agar-
ose gel to recover products with inserts of ~200 bp.
Quality control was performed by cloning an aliquot of
the library into a TOPO plasmid and capillary sequen-
cing eight clones per library. The samples were then used
to generate DNA colonies using one channel of a paired-
end flow cell at dilutions of 4 pM. The flow cell was then
submitted to 2 × 74 cycles of sequencing on the genome
analyzer. Base calling was performed using the GAPipe-
line 1.4.0 software; a total of 27.6 million reads (pass fil-
ter) were obtained. After bar code selection, 13.9 and
11.8 million reads of 71 bases in length were obtained for
the strains O11 and O46 respectively. The pool of
sequences obtained was analyzed and assembled using
the Edena assembler [13], which resulted in a set of 87
and 96 contigs for O11 and O46, respectively. The gene
content of each strain (2787 and 2822 Coding Sequences
-CDSs- for O11 and O46, respectively) was thus estab-
lished and used in protein identification after SERPA.
Detailed genome analysis of these strains is described
elsewhere (Le Maréchal et al., submitted).
2-Dimensional Electrophoresis (2-DE)
Samples (200 μg of proteins for Coomassie blue staining
and 50 μg for Western blotting) were precipitated with 2D
Table 1 Staphylococcus aureus strains used in this study
Strain Type of mastitis Origin Isolated in:
O11* gangrenous south east France 2002
1628 gangrenous south east France 2010
1624 clinical south east France 2003
1625 clinical south east France 2008
1626 clinical south east France 2008
1536 clinical south west France 1998
O46* subclinical south east France 2002
1627 subclinical south east France 2008
O55 subclinical south east France 2003
O117 subclinical Corsica. France 2001
1535 subclinical south west France 1998
O82 subclinical south east France 2003
*: O11 and O46 were used for experimental infections and their genome was
fully sequenced (see Materials and Methods).
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the manufacturer’s instructions. Pellets were solubilised in
sample solution containing 7 M urea, 2 M thio-urea,
25 mM dithiothreitol (DTT), 4% (w/v) 3-[(3-Cholamido-
propyl)dimethylammonio]-1-propane-sulfonate (CHAPS)
and 2% (w/v) ampholyte containing buffer (IPG-Buffer 4-7
or 3-10 NL, GE Healthcare). Isoelectric focusing was car-
ried out using pH 4 to 7 (Cell wall and total proteins) or 3
to 10 NL (exoproteins) 13 cm Immobiline Dry Strips on a
Multiphor II electrophoresis system (Amersham Bios-
ciences; GE Healthcare, Orsay, France) for a total of 60
kVh using a standard procedure described previously [14].
The second dimensional separation was performed on the
Ettan™ DALTtwelve electrophoresis system (GE Health-
care) using 14% acrylamide separating gels without a
stacking gel at a voltage of 50 V for 1 h and 180 V for
about 7 h. Kaleidoscope Prestained Standards (Biorad)
were used as standard. Gels were transferred onto mem-
brane or stained with R250 Coomassie blue (Serva, Heil-
delberg, Germany) or MS-compatible silver nitrate
(Sigma) [15].
Intramammary challenge with S. aureus in ewes
Experimental mastitis was performed according to the
Regional Committee for Animal Use and Care (Côte
d’Azur, France) and is recorded under reference NCA/
2008-14/12-09. Healthy lactating primiparous ewes of
Lacaune breeds were selected based on the absence of
intramammary infections and milk somatic cell counts
below 100 000 cells/mL. Repeated full bacteriological
analysis of milk from the two quarters that were going
to be infected showed that the ewes were negative for
Staphylococcus sp. and Mycoplasma sp. Absence of
nasal carriage for staphylococci was also checked after
enrichment and culturing of swab samples of the nares
of ewes on selective media, as described previously [6].
At D0, 12 ewes were divided into 2 groups and urethral
catheters (Portex
® Jackson Cat Catheter, Coveto,
France) were inserted into the teat canal after a thor-
ough disinfection of the teat orifice with 70% ethanol.
1 mL PBS containing 20 CFU of S. aureus (O11 or
O46) was injected through the catheter, which was
removed afterwards. Six ewes were thus infected by
s t r a i nO 1 1( g r o u pO 1 1 )a n ds i xb ys t r a i nO 4 6( g r o u p
O46). Severity of the mastitis induced in ewes was esti-
mated according to criteria presented in Additional file
1, Table S1. Mastitis was classified as subclinical, clini-
cal, pyogenic and gangrenous. Classification was based
on clinical symptoms, presence of S. aureus cells and
Somatic Cell Count (SCC) in milk.
Sample processing
Sera from ewes were prepared from blood samples col-
lected aseptically from the jugular vein of the animals at
D0, D7, D14, D21 and D28 post inoculation (pi). Briefly,
blood samples were kept for 2 h at room temperature
before centrifugation. Sera were then stored at -20°C.
Milk samples were taken 24 and 36 h pi for bacteriolo-
gical examination and determination of SCC. Milk was
1/10 diluted and 100 μL of this dilution was plated on
selective Rabbit Plasma Fibrinogen Baird-Parker medium
to confirm S. aureus presence in the mammary gland.
SCC was measured with the Fossomatic method [16] to
follow the onset of the infection.
Western blot analysis
Total cell lysates were prepared as previously described
[11]. Total protein extracts of S. aureus strains O11 and
O46 were separated by SDS-PAGE on 12% acrylamide
separating slab gels (70 × 100 × 0.5 mm), with a 4% acry-
lamide stacking gel on a mini-protean III gel system
(BioRad, Ivry sur Seine, France) according to Laemmli
[17]. Protein migration was performed for 2 h at room
temperature at constant 80 V voltage. Samples were
d i l u t e di ns a m p l eb u f f e ra n dd e n a t u r e da t1 0 0° Cf o r
3 min. Gels were transferred onto a PVDF membrane
(GE Healthcare) at constant 250 mA amperage in Tow-
b i nt r a n s f e rb u f f e r[ 1 8 ]u s i n gaT r a n s - B l o tc e l l( B i o r a d )
for 1.25 h. Membranes were washed three times with
Tris Buffered Saline (TBS) at pH 7.5 and saturated in
blocking solution (3% non-fat dry milk in TBS with 0.3%
Tween 20 (TBS-T)) at 4 °C overnight. After saturation in
blocking solution, membranes were washed 3 × 10 min
with TBS-T and exposed to the different ewe sera used
as primary antibody for 4 h at room temperature. After
washing, membranes were incubated with alkaline phos-
phatase conjugated anti-sheep IgG (Sigma) diluted
1:15,000 in 25 mL blocking solution for 1 h and finally
BCIP/NBT (Sigma) was used to visualize immunoreactive
proteins, according to the manufacturer’s instructions.
Selection of the hyper-immune sera
Sera samples were analysed by western blotting as
described above. Sera sampled on D0, D7, D14, D21 and
D28 pi were compared using the mini-protean II Multi-
screen apparatus (Biorad) (600 μLo fs e r u md i l u t e d
1:10,000 in blocking solution). Immunostained Western
blots were scanned using an Image Scanner II (Amersham
biosciences) and further analyzed using Image- Quant 1D
software. The number, volume and area of bands were
taken into account for the analysis. Optimal dilution for
the selected sera was determined as described above. Sera
and dilutions yielding the best ratio signal/background
were selected.
Identification of immunoreactive proteins
Bacterial proteins separated by 2-DE were transferred
onto a PVDF membrane (GE Healthcare) as described
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parallel. Three gels were used for immunoblotting, and
the fourth one was Coomassie blue-stained for spot
matching and further identification. After saturation in
blocking solution the membranes were treated with
selected sera in blocking solution during 4 h. Then, the
membranes were washed with TBS-T and incubated
with alkaline phosphatase conjugated anti-sheep IgG
(Sigma) diluted 1:15 000 in 25 mL blocking solution for
1 h. Finally BCIP/NBT (Sigma) was used to visualize
immunoreactive proteins, according to the manufac-
turer’s instructions. Membranes were scanned using an
Image Scanner II (Amersham biosciences) and further
analyzed using Image- Master 2D software. Immunoblot
profiles for 2-DE-separated proteins were reproducible
in at least two individual experiments. Images of the 2D
electrophoresis gels and the BCIP-NBT treated mem-
branes were compared to detect immunoreactive pro-
teins. Spots that were absent or had a significantly
different intensity in one strain were considered as pro-
teins that differed between O11 and O46. Spots corre-
sponding to proteins of interest were excised and
identified using Nano-Liquid Chromatography (Nano-
LC) MS/MS analysis.
Nano-LC MS/MS analysis
Proteins were identified by tandem mass spectrometry
(MS/MS) after an in-gel trypsin digestion adapted from
Shevchenko [19]. Briefly, gel pieces were excised from
the gel, washed with acetonitrile and ammonium bicar-
bonate solution, and then dried under vacuum in a
SpeedVac concentrator (SVC100H-200; Savant, Thermo
Fisher Scientific, Waltham, MA, USA). In-gel trypsin
digestion was performed overnight at 37 °C and stopped
with spectrophotometric-grade trifluoroacetic acid
(TFA) (Sigma-Aldrich). The supernatants containing
peptides were then vacuum dried in a Speed-Vac con-
centrator and stored at -20 °C until mass spectrometry
analysis. Nano-LC experiments were performed using an
on-line liquid chromatography tandem mass spectrome-
try (MS/MS) setup using a Dionex U3000-RSLC nano-
LC system fitted to a QSTAR XL (MDS SCIEX, Ontario,
Canada) equipped with a nano-electrospray ion source
(ESI) (Proxeon Biosystems A/S, Odense, Denmark).
Samples were first concentrated on a PepMap 100
reverse-phase column (C18, 5 μm, 300-μm inner dia-
meter (i.d.) by 5 mm length) (Dionex, Amsterdam, The
Netherlands). Peptides were separated on a reverse-
phase PepMap column (C18, 3 μm, 75 μmi . d .b y1 5 0
mm length) (Dionex) at 35 °C, using solvent A (2% (vol/
vol) acetonitrile, 0.08% (vol/vol) formic acid, and 0.01%
(vol/vol) TFA in deionized water) and solvent B (95%
(vol/vol) acetonitrile, 0.08% (vol/vol) formic acid, and
0.01% (vol/vol) TFA in deionized water). A linear
gradient from 10 to 50% of solvent B in 40 min was
applied for the elution at a flow rate of 0.3 μL/min.
Eluted peptides were directly electrosprayed into the
mass spectrometer operated in positive mode. A full
continuous MS scan was carried out followed by three
data-dependent MS/MS scans. Spectra were collected in
the selected mass range 400 to 2 000 m/z for MS and
60 to 2 000 m/z for MS/MS spectra. The three most
intense ions from the MS scan were selected individually
for collision-induced dissociation (1+ to 4+ charged ions
were considered for the MS/MS analysis). The mass
spectrometer was operated in data-dependent mode
automatically switching between MS and MS/MS acqui-
sition using Analyst QS 1.1 software. The instrument
was calibrated by multipoint calibration using fragment
ions that resulted from the collision-induced decomposi-
tion of a peptide from b-casein, b-CN (193-209). The
proteins present in the samples were identified from MS
and MS/MS data by using MASCOT v.2.2 software for
search into two concatenated databases: (i) a homemade
database containing all the predicted proteins of the S.
aureus strains O11 and O46 used in this study and (ii) a
portion of the UniProtKB database corresponding to the
S. aureus taxonomic group [20]. Search parameters were
set as follows. A trypsin enzyme cleavage was used, the
peptide mass tolerance was set to 0.2 Da for both MS
and MS/MS spectra, and two variable modifications
(oxidation of methionine and deamidation of asparagine
and glutamine residues) were selected. For each protein
identified in NanoLC-ESI-MS/MS, a minimum of four
peptides with MASCOT score corresponding to a P
value below 0.05 or an Exponentially Modified Protein
Abundance Index [21] greater than 0.4 were necessary
for validation with a high degree of confidence. For
automatic validation of the peptides from MASCOT
search results, the 1.19.2 version of the IRMa software
was used [22].
Intramammary infection with S. aureus in mice
The animal study was conducted according to current
Good Scientific Practice-principles (2000) and approved
by the Ethical Committee of the Faculty of Veterinary
Medicine, Ghent University (Belgium). Sixteen CD-1
lactating female mice (Harlan Laboratories Inc., Horst,
The Netherlands) were used 12-14 days after birth of
the offspring. The pups were removed 1 to 2 h before
bacterial inoculation of mammary glands and a mixture
of ketamine/xylazine was used for anesthesia of the lac-
tating mice. The orifice of both L4 (on the left) and R4
(on the right) abdominal mammary glands was exposed
by a small cut at the near end of the teat. 100 μLP B S
without (n = 2) or with 150 CFU of S. aureus strain
O11 (n =7 )o rO 4 6( n = 7) was injected slowly with a
32-gauge blunt needle through the teat canal. Rectal
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1 8hp i .A t1 8hp im i c ew e r ea n e s t h e t i z e dw i t hk e t a -
mine/xylazine to collect blood by cardiac puncture and
serum was obtained after clotting at 37 °C and cold cen-
trifugation. After cardiac puncture, mice were eutha-
nized by cervical dislocation and mammary glands were
isolated. Glands of six mice of each group were homo-
genated and bacterial CFU was quantified by plating
serial logarithmic dilutions in PBS. Lysates from the
homogenates were prepared in 1% NP40-based buffer.
Serum and mammary gland lysates were quantified for
IL-1b, IL-6, TNF, KC and MCP-1 using BD
™ Cyto-
metric Bead Array technology. Mammary glands (inocu-
lated and PBS control glands) of 4 mice (2 from each
group) were embedded and used for further histopatho-
logical analysis (Vetopath, Antibes, France).
Statistical analyses
A Fisher test was used with a risk a = 10% to determine
the difference between the ewes infected with S. aureus
O11 and the ewes infected with strain O46. Differences
in rectal body temperature and cytokine levels in the
mouse mastitis model were analyzed with the unpaired
T-test. P < 0.05 was considered statistically significant.
Results
Ewes infected with O11 or O46 S. aureus strains
developed mastitis with different severities
Although O11 and O46 strains share the same genotype
and are highly genetically similar [10], they were isolated
from dramatically different ewe mastitis episodes. One
can thus wonder whether the clinical signs associated
with O11 and O46 infection were or not related to
strains characteristics or a fortuitous matter of sampling
time (mastitis can indeed evolve from subclinical to
severe clinical or even gangrenous within a few days).
To check this, two groups of ewes were infected either
with O11 or O46 S. aureus strains, as described in the
previous section. Onset of the symptoms was followed
up during the course of the experiment. All animals
became infected and signs of mastitis were evident in
most ewes as soon as 24 h pi. The animals shed the
S. aureus strains over the sampling period and remained
infected for the duration of the experiment. Shedding
from the infected glands varied and S. aureus load in
milk ranged from 10 CFU/mL to 3.16 × 10
8 CFU/mL,
depending on the individual ewe, and on the day pi (not
shown). Symptoms evoked by intramammary inocula-
tion varied among ewes. In group O11, five out of six
ewes developed a gangrenous mastitis, the last one
developed a pyogenic mastitis according the criteria
defined in Additional file 1, Table S1. In group O46,
symptoms were more heterogeneous and mastitis cases
were classified in subclinical mastitis (n = 1), pyogenic
mastitis (n = 2), mild clinical mastitis (n =2 )a n dg a n g -
renous mastitis (n = 1). Subclinical mastitis was deter-
mined with the presence of bacteria (250 CFU/mL of
milk 36 h pi), a raise in SCC (> 200 000 cells/mL in
each milk sample after 24 h) and absence of fever or
symptoms. Except for the ewe with subclinical mastitis,
bacteria were detected in all milk samples and reached
more than 10
6 CFU/mL 36 h pi. All animals had fever
(above 40 °C 36 h pi) and SCC increased quickly and
was above 10
6 cells/mL at 36 h pi. The proportion of
the gangrenous mastitis was significantly higher in the
group of ewes infected with O11 strain compared to the
g r o u pi n f e c t e dw i t hO 4 6( p = 0.08) (Additional file 2,
Figure S1).
S. aureus O11 and O46 induce dramatically different
clinical features in infected mice. To confirm our obser-
vation that S. aureus strains O11 or O46 induce differ-
ent types of mastitis, the mouse mastitis model was
employed in the current study. Strains O11 and O46
grew equally well in the infected mouse mammary
glands and induced mastitis, as determined by tempera-
ture measurement (hypothermia in O11 group and
hyperthermia in O46 group, 24 h pi; Additional file 3,
Figure S2) and histopathological analysis: polymorpho-
nuclear neutrophils (PMN) infiltration was observed
only in infected (either with O11 or O46 strains) mam-
mary gland tissue (not shown). To analyse the role of
each strain in the development of mastitis, cytokine pro-
file of the serum and mammary gland tissue lysates of
mice infected with O11 strain was compared to those
infected with O46 strain. The results of cytokine quanti-
fication showed that mice infected with S. aureus O46
had significantly higher IL-1b and TNF levels in the
mammary gland lysates and significantly higher systemic
(serum) levels of IL-1b and MCP-1 (Additional files 4
and 5, Figures S3 and S4). Altogether, these results
demonstrate that despite their close genetic relation-
ships, S. aureus O11 and O46 reproducibly induced
mastitis with significantly different clinical signs.
Antibody production in response to infection of ewes
with S. aureus strains O11 or O46
To compare the relative level of antibodies developed in
response to S. aureus presence in the mammary gland,
serum sampled on D0, D7, D14, D21 and D28 pi were
analysed by Western blotting using either O46 or O11
total bacterial extracts as described in the previous sec-
tion. The number of bacterial proteins recognised by
sera and signal intensity increased from D0 to D28 for
both O11 and O46 samples (Figure 1). The intensity of
the signal revealed with sera collected on D0 was low
and much weaker compared to those obtained with sera
collected on D21 or D28. Western blots membranes
were analysed as described in the previous section. Sera
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analysis. Sera yielding the best signals in each group
(one sample for each of the six ewes) were pooled to be
used in SERPA experiments. Two pools were thus
obtained: sera from ewes infected with O11 and sera
from ewes infected by O46, hereafter referred to as
group O11 sera and group O46 sera, respectively.
Detection and identification of immunogenic
staphylococcal proteins by SERPA
Protein samples were prepared from O11 and O46
strains grown in conditions that best mimic the mastitis
context [11]. Each fraction (total, cell wall and superna-
tant) of O11 and O46 culture was immunoblotted using
either group O11 or group O46 sera. Altogether, 89 pro-
teins were identified as immunoreactive (Table 2). Com-
parison of SERPA results (see Figure 2, and Additional
files 6 and 7, Figures S5 and S6) on the three fractions
analyzed showed that immunoreactive proteins were
mainly identified in supernatant samples prepared from
aerobic and anaerobic cultures (Figure 2 and Additional
file 7, Figure S6) and cell wall samples (Additional file 6,
Figure S5, upper panels) whereas total protein samples
were poorly recognized (Additional file 6, Figure S5,
lower panels). A vast majority of the immunoreactive
proteins are thus found in supernatant and cell wall frac-
tions (88.7%), and only 11.3% are found in the total frac-
tions (Figure 3A). Of note, secreted and surface proteins
are expected to be exposed to the host immune system.
The predicted location of the proteins (according to the
SurfG+ analysis of O11 and O46 genome sequences)
[23], showed that the immunoreactive proteins were
mainly predicted cytoplasmic (52.8%) (Figure 3A). Pro-
teins were classified into categories based on functional
annotation (Figure 3B). Most immunogenic proteins
identified here are found in various functional categories
involved in cellular machinery and metabolism; while
20% were virulence factors and virulence associated
proteins.
Composition of the core and accessory seroproteomes
SERPA revealed 74 proteins as being recognised by both
group O11 and group O46 sera (Table 2). These proteins
defined the core seroproteome, i.e. a pool of staphylococ-
cal proteins that are recognized by the host immune sys-
tem in both S. aureus strains (Figure 3C). Moreover, 15
proteins were differentially recognized by group O11 sera
or by group O46 sera. These proteins defined the acces-
sory seroproteome, i.e. a pool of strain-specific proteins
that are recognized by the host immune system. Among
these 15 proteins, 12 appeared to be immunogenic only in
infections with O11 (Table 2). These proteins include 7
virulence-associated proteins (Sbi, SspB, SspA, Aur, IsdH,
Opp1A, and VWbp), 2 stress response proteins (AhpF,
TrxB), 1 hypothetical protein (product of CDS O11_0736
or O46_1969 in O11 or O46), Ldh and a cysteine synthase.
Of note, when considering the corresponding genes, all of
these 12 genes are present and highly similar in O11 and
O46 strains. Only ahpF and vwbp present 2 and 1 non-
synonymous single nucleotide polymorphisms (NS-SNPs),
respectively. These results suggest that O11 produce these
12 proteins in vivo in a mastitis context whereas O46 does
not, or to a much lesser extent. Three proteins appeared
to be immunoreactive with group O46 sera only. Two of
them are hypothetical proteins corresponding to
SAOV0649 (CDS 011_2290 and 046_0078, in O11 and
O46, respectively) encoding a probable esterase or lipase,
and a gene 011_0490/046_2740 with no homology in
ED133 genome sequence. The third protein is IsaA, a viru-
lence-associated immunodominant antigen A. The genes
encoding IsaA and the probable esterase or lipase are
highly homologous in O11 and O46 with only 1 synon-
ymous SNP found when comparing O11_2290 and
O46_0078. Interestingly, the CDS O11-0490 in O11 gen-
ome shares homology with O46_2740 in O46. However,
sequence analysis reveals that O11-0490 corresponds to a
truncated form of O46_2740. This gene encodes a pre-
dicted protein that presents 59% identity and 76% homol-
ogy with exfoliative toxin D [24].
D0 D7 D14 D21D28
O11
D0 D7 D14 D21D28
O46
Figure 1 Western blot analysis of total lysates of S. aureus O11
(left panel) or S. aureus O46 (right panel) using D0, D7, D14,
D21, D28 diluted 1:10,000 sera of ewes infected by O11 and
O46. Bacteria were grown in iron-depleted RPMI without aeration
to late exponential phase. Protein samples were prepared from total
cell, submitted to 1-DE, western blotted on PVDF membrane and
revealed using each of the 6 serum samples collected on ewes
infected in each group. One representative example is given for
each group of infected ewes (with O11 or O46).
Le Maréchal et al. Veterinary Research 2011, 42:35
http://www.veterinaryresearch.org/content/42/1/35
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Description
1 Spots
2 O11
CDS
3
O46
CDS
3
ED133 CDS
3 pI
4 Mass
(Da)
5
Score
6 Cov.
7 #pep.
8 EmPAI
9 Comp.
10 Loc.
11 Immun.
12
Metabolism
Energy production and
conversion
formate acetyltransferase 81, 83, 82 011_0041 046_0511 SAOV_0163 5,31 84808 1301,60 34,31 22 1,57 CW C
ldh L-lactate dehydrogenase 82, 99, 81, 83, 95 011_0136 046_0198 SAOV_2646c 4,80 34389 1749,37 63,64 26 21,75 CW C [82]
L-LACTATE DEHYDROGENASE
(O11)
64 011_0021 046_0531 SAOV_0178 5,00 34548 745,83 50,79 14 2,59 S C [82]
bifunctional acetaldehyde-CoA/
alcohol dehydrogenase
79 011_0796 046_0709 SAOV_0095 5,68 94945 2090,64 45,45 33 2,26 CW C
D-3-phosphoglycerate
dehydrogenase
100 011_0585 046_1131 SAOV_2344 5,32 34652 717,85 43,53 11 1,72 CW C
atpD F0F1 ATP synthase subunit
beta
62, 90 011_2064 046_0898 SAOV_2144c 4,68 51368 631,03 30,21 10 0,98 S,CW C [83]
Nucleotide transport
and metabolism
adk adenylate kinase 9 011_0510 046_1206 SAOV_2266c 4,80 23375 531,72 42,38 9 2,80 S C [84]
deoD purine nucleoside
phosphorylase
9 011_1051 046_0577 SAOV_2178 4,85 25892 470,94 53,39 8 1,97 S C [4]
guaB inositol-monophosphate
dehydrogenase
102, 129 011_0077 046_0960 SAOV_0412 5,61 52818 1237,95 54,30 20 3,52 CW,T C [4]
Carbohydrate transport
and metabolism
gpmA 2,3-bisphosphoglycerate-
dependent phosphoglycerate
mutase
131 011_1952 046_0264 SAOV_2463c 5,23 26663 271.65 30.26 5 0.80 S,T C
eno enolase 2-phosphoglycerate
dehydratase
62, 88, 90, 96, 137 011_2336 046_2241 SAOV_0818 4,55 47088 1868,52 63,59 25 7,09 S,CW,T C [4,52,85-87]
fda fructose-1,6-bisphosphate
aldolase
107, 94, 72, 91, 95 011_0131 046_0202 SAOV_2650 5,06 32878 852,09 46,62 13 2,48 CW,S C [85-88]
gap glyceraldehyde-3-phosphate
dehydrogenase
99, 57, 81, 82, 83 011_2340 046_2237 SAOV_0814 4,89 36258 940,06 46,13 13 3,04 CW,S C [82,86,87,89,90]
putative translaldolase 9 011_1872 046_2451 SAOV_1765 4,72 25689 554,11 46,84 10 3,32 S C
tpiA triosephosphate isomerase 9 011_2338 046_2239 SAOV_0816 4,81 27271 1396,16 76,28 21 16,78 S C [4,91,92]
atl autolysin 23, 31 011_1991 046_0320 SAOV_0999c 9,59 136983 2567,68 42,14 42 1,87 S S [52,76,93]
pyk pyruvate kinase 105 011_1282 046_0580 SAOV_1685 5,23 63067 271,45 11,62 5 0,29 CW C [94]
Lipid metabolism
fabZ 3R-hydroxymyristoyl ACP
dehydratase
126 011_2356 046_1839 SAOV_2140c 5,71 16071 86,65 13,70 2 0,47 T C
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0Table 2 Proteins identified in this study (Continued)
acetoin reductase 106 011_1332 046_1393 SAOV_0074 5,04 27199 566,84 40,31 7 1,82 CW C
Amino acid transport
and metabolism
dipeptidase PepV 62 011_1904 046_1329 SAOV_1737 4,56 52762 235.33 10.66 4 0,27 S C
CYSTEINE SYNTHASE (O11) 64 011_1382 046_2402 SAOV_0535 5,38 32955 266.80 28.71 5 0,61 S C
Information storage
and processing
Translation, ribosomal structure
and biogenesis
fus elongation factor G 95 011_0401 046_1769 SAOV_0582 4,80 76564 2173,77 68,11 30 4,11 CW C [3,90]
prs 50S ribosomal protein L25/
general stress protein Ctc
94 011_1370 046_2414 SAOV_0523 4,39 23773 384,17 34,56 6 2,26 CW,S C [95]
rplC 50S ribosomal protein L3 131 011_0531 046_1185 SAOV_2287c 9,72 22648 482,78 42,11 9 2,95 T C [95]
rpsA 30S ribosomal protein S1 137, 62, 121, 171 011_2142 046_1743 SAOV_1482 4,51 43252 1555,46 71,36 23 6,25 S,CW,T C [39,95]
rpsD 30S ribosomal protein S4 139 011_1260 046_1365 SAOV_1706 10,02 22999 428,22 40,50 8 1,96 T C [95]
rplB 50S ribosomal protein L2 91 011_0528 046_1188 SAOV_2284c 10,77 30136 239,93 25,27 5 0,69 CW C [95]
tsf elongation factor Ts 100, 64 011_0909 046_0755 SAOV_1259 5,05 32474 436,02 31,06 7 0,97 CW,S C [4,86,93,96]
tuf elongation factor Tu 90, 88, 96, 10, 122, 137,
149, 81, 82, 83, 95
011_0402 046_1768 SAOV_0583 4,74 43077 2665,48 84,26 38 52,14 S,CW,T C [3,52,82,85,86,90,93,96]
yfiA ribosomal subunit interface
protein
106 011_2483 046_1255 SAOV_0789 5,25 21511 376,75 35,33 6 1,76 CW C
aspS aspartyl-tRNA synthetase 63 011_2454 046_2303 SAOV_1627 4,99 66584 233,90 7,65 4 0,21 S C
alaS alanyl-tRNA synthetase 82 011_2466 046_2291 SAOV_1616 5,00 98604 442,31 11,74 8 0,30 O C [97]
Transcription
nusA transcription elongation
factor NusA
62 011_0919 046_0765 SAOV_1268 4,60 43701 247,74 11,00 4 0,34 S C
DNA replication, recombination
and repair
dnaN DNA polymerase III subunit
beta
90 011_1166 046_1471 SAOV_0002 4,66 41888 706,28 45,62 11 1,30 CW C
nuc staphylococcal
thermonuclease precursor
151, 108, 5, 153, 206, 207,
217
011_2070 046_2528 SAOV_0832 9,20 25089 967,00 50,00 20 14,46 S,CW PSE [98]
ruvA Holliday junction DNA
helicase
66 011_2442 046_2315 SAOV_1639 5,77 22249 137,72 17,00 3 0,52 S C
Posttranslational modification,
protein turnover, chaperones
ahpC alkyl hydroperoxide
reductase subunit C
67, 82, 83, 99, 95 011_0085 046_0968 SAOV_0404c 4,88 20963 667,36 56,08 11 4,95 S,CW C [93]
AhpF ALKYL HYDROPEROXIDE
REDUCTASE SUBUNIT F (O11)
97, 86 011_0086 046_0969 SAOV_0403c 4,68 54655 2242,14 67,06 34 9,91 CW C
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0Table 2 Proteins identified in this study (Continued)
dnaK chaperone protein 96, 173, 137 011_2230 046_2216 SAOV_1580 4,63 46021 2907,83 80,29 43 24,66 S,CW,T C [90,96,99]
peptidyl-prolyl cis-isomerase 212, 1, 68, 91 011_2089 046_2477 SAOV_1837 9,01 35602 574,32 31,56 11 1,66 S,CW PSE
tig trigger factor 105 011_1304 046_0602 SAOV_1664 4,34 48565 1061,87 61,43 17 2,25 CW C [94]
TrxB THIOREDOXIN REDUCTASE
(O11)
64 011_2580 046_2228 SAOV_0801 5,21 33595 681,95 33,76 11 1,81 S C [93]
Cellular processes
Cell envelope biogenesis, outer
membrane
IsaA IMMUNODOMINANT
ANTIGEN A (O46)
185, 8, 161, 186, 9, 164,
189
011_0168 046_0166 SAOV_2614c 5,91 24219 1516,56 59,23 22 40,99 S S [3,75]
isdA iron-regulated cell wall-
anchored protein
31, 27, 73, 74, 75, 83, 118,
79, 81, 82, 95
011_1476 046_1296 SAOV_1125c 8,69 70445 2288,12 57,87 38 6,04 S,CW PSE [100-102]
isdB cell surface transferrin-binding
protein
212, 211, 210, 208, 193,
156, 138, 110, 70, 86, 131,
156, 193
011_1477 046_1295 SAOV_1126c 9,54 39197 886,30 45,48 15 4,45 S,CW,T PSE [54,100,103]
IRON-REGULATED SURFACE
DETERMINANT PROTEIN H (O11)
55, 31 011_1248 046_1353 SAOV_1717 5,05 100650 2209,72 42,11 37 2,58 S PSE [75]
IsdD iron-regulated protein 15, 16 011_1480 046_1292 SAOV_1128 8,51 41357 278,05 15,36 5 0,47 S PSE
Cell motility and secretion
N-acetylmuramoyl-L-alanine
amidase
52, 51, 187 011_1090 046_1546 SAOV_2693 5,87 69226 3097,93 71,57 43 16,52 S S [57,75,76]
Inorganic ion transport and
metabolism
nasE assimilatory nitrite reductase 10 011_1932 046_0245 SAOV_2445c 4,95 11430 126,05 23,08 2 0,70 S C
mntC Manganese/iron transport
system substrate-binding protein
94 011_2274 046_0062 SAOV_0666c 8,68 34719 1183,08 51,46 20 10,68 S,CW PSE
sirA iron-regulated lipoprotein 135, 64 011_1345 046_1405 SAOV_0062 9,20 36735 609,79 35,45 11 1,58 S,T PSE [104]
fhuD2 ferrichrome-binding protein 91 011_0566 046_1150 SAOV_2323c 9,16 33990 406,75 30,13 8 1,10 CW PSE [105]
ferrichrome ABC transporter
lipoprotein
91 011_1857 046_1674 SAOV_2224c 9,44 36751 600,45 38,41 11 1,57 CW PSE
Signal transduction mechanisms
SA1540 GAF domain-containing
protein
10 011_1261 046_1366 SAOV_1705 5,09 17042 139,34 22,73 3 0,72 S C
Universal stress response protein 7, 123 011_1269 046_1374 SAOV_1697 5,60 18463 973,68 78,31 12 19,34 S,CW C [106]
Toxins and haemolysins
beta-hemolysin 15, 19, 205 011_1750 046_2394 SAOV_2040 8,75 37386 1308,79 61,03 20 4,92 S S [57,107]
hla alpha-hemolysin precursor 13, 1, 15, 19, 21, 68, 72,
107, 146, 153
011_1514 046_1259 SAOV_1161c 8,87 36329 2238,72 76,71 34 44,90 S,CW,T S [93,107]
hlgC gamma-hemolysin
component C
68, 1 011_1956 046_0268 SAOV_2469 9,29 35562 765,07 31,43 12 1,90 S,CW S [57]
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0Table 2 Proteins identified in this study (Continued)
Virulence/defence mechanisms
Sbi IGG-BINDING PROTEIN
SBI (O11)
216, 217, 212 011_1954 046_0266 SAOV_2466 9,38 49998 984,16 41,74 18 2,80 S S [76]
SspB CYSTEINE PROTEASE
PRECURSOR (O11)
58, 57, 64, 182, 215 011_2154 046_0327 SAOV_0993c 5,45 42714 2027,86 65,52 30 11,52 S S [4]
SplF serine proteinase 4 011_0672 046_2496 SAOV_1795 9,36 25638 255,88 23,01 5 0,84 S S [108]
lukD leukotoxin D subunit 1 011_0685 046_2484 SAOV_1812 9,14 36936 365,37 22,02 7 0,98 S S [109]
lukE leukotoxin E subunit 1, 68 011_0686 046_2483 SAOV_1813c 9,38 34126 451,11 17,65 7 1,77 S,CW S [109]
leukocidin chain lukM precursor 68, 1, 120, 145, 177, 194,
201, 202, 94
011_1215 046_2777 SAOV_1909 9,41 35054 2504,69 71,43 35 29,80 S,CW,T S [58,110]
leukocidin F subunit 16, 70 011_1752 046_1972 SAOV_2041 8,29 38639 1154,65 45,27 19 11,64 S,CW S [58,110]
leukocidin S subunit 199, 5, 70, 108, 109, 197,
200, 211
011_1753 046_1973 SAOV_2042 9,38 40379 1399,91 55,56 23 6,70 S,CW S [58,110]
Panton-Valentine leukocidin LukF-
PV chain precursor
1, 68, 70, 15, 31, 119, 195,
203, 204, 10, 91
011_1216 046_2776 SAOV_1908 9,16 36496 965,38 50,31 15 3,37 S,CW S [58,110]
plc 1-phosphatidylinositol
phosphodiesterase
11, 12, 19 011_1424 046_1419 SAOV_0049 7,12 37030 2759,20 71,95 44 84,00 S S [4]
Aur ZINC METALLOPROTEINASE
AUREOLYSIN (O11)
220, 63 011_1083 046_1553 SAOV_2686c 4,98 54947 921,93 47,39 17 1,68 S C [76,111]
Opp1A OLIGOPEPTIDE
TRANSPORTER SUBSTRATE
BINDING PROTEIN (O11)
86 011_2424 046_2102 SAOV_2517c 8,33 59224 1398,01 47,53 24 3,28 CW PSE
SspA GLUTAMYL
ENDOPEPTIDASE SERINE
PROTEASE (O11)
56, 184, 214 011_2155 046_0325 SAOV_0994c 4,68 32250 1575,55 69,26 24 24,18 S C [57]
SECRETED VON WILLEBRAND
FACTOR-BINDING PROTEIN (O11)
22 011_2679 046_0987 SAOV_2051c 8,39 57935 1122,89 36,67 17 1,70 S S
epidermal cell differentiation
inhibitor B
208, 209, 193, 156, 4 011_0489 046_2741 9,51 27969 1385,18 69,32 22 22,31 S S
Miscellaneous
adhA alcohol dehydrogenase 100 011_1554 046_0086 SAOV_0640 5,34 36025 1167,82 66,37 16 4,30 CW C [87,93]
exported secretory antigen
precursor
67 011_0584 046_1132 SAOV_2343 5,77 17388 397,17 33,13 5 1,43 S S
lip triacylglycerol lipase precursor 31, 27 011_1119 046_1518 SAOV_2721c 8,13 76637 1723,17 50,95 29 2,36 S S [93]
mqo malate:quinone
oxidoreductase
128 011_0130 046_0203 SAOV_2651c 6,12 55964 1047,99 46,79 17 2,50 T C
putative staphylococcal enterotoxin 151 011_0097 046_0981 SAOV_0394 9,54 23311 173,20 18,72 4 0,71 S S
Unknown
HYPOTHETICAL PROTEIN (O11) 220 011_0736 046_1969 SAOV_0454 4,89 56229 823,11 39,40 14 1,21 S S
hypothetical protein (Similar to
truncated map-w protein (91%))
88, 10, 62 011_1749 046_2393 9,91 53686 899,64 34,52 18 2,09 S,CW S [112]
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0Table 2 Proteins identified in this study (Continued)
hypothetical protein (Similar to
beta-lactamase (84%))
10 011_0679 046_2490 6,84 20800 726,52 47,15 10 7,09 S S
HYPOTHETICAL PROTEIN (O46) 157, 160, 175, 189, 193 011_0490 046_2740 8,88 30854 2343,27 74,29 41 65,07 S S
hypothetical protein (Similar to
probable glutamyl-endopeptidase
(76%))
66 011_0488 046_2742 5,44 20552 741,93 47,62 12 5,11 S C
SA0570 HYPOTHETICAL PROTEIN
(O46)
219,154, 127 011_2290 046_0078 SAOV_0649 9,17 18554 815,59 69,05 13 15,93 S,CW S
SA0663 hypothetical protein 10, 164, 94 011_2561 046_2636 SAOV_0742c 9,15 16047 457,11 35,62 8 3,63 S PSE
SA0914 hypothetical protein 6 011_2000 046_0311 SAOV_1008c 6,55 11338 522,48 57,14 8 13,10 S S
pathogenicity island protein 55 011_2741 046_0985 SAOV_0429 9,55 12071 204,61 19,64 3 1,12 S S
SA1607 hypothetical protein 91 011_1867 046_2456 SAOV_1770 6,04 34973 232,41 16,56 4 0,43 CW S
SA1402 hypothetical protein 91 011_2223 046_2209 SAOV_1573 5,60 35160 448,93 28,27 6 0,72 CW S
Gene products of the accessory seroproteome are indicated in bold capital letters, (O11) indicates O11-specific proteins, (O46) indicates O46-specific proteins.
All the other proteins belong to the core seroproteome.
1: Proteins are classified in Gene Ontology functional classes. Names are given according to annotation of available S. aureus sequence genomes.
2: Spot number (see figures).
3: Coding sequence numbers corresponding to the identified proteins in S. aureus O11, S. aureus O46, and ED133, respectively.
4: Theoretical isoelectric point as determined from the predicted protein sequence.
5: Theoretical Mass as determined from the predicted protein sequence.
6: Mascot standard score.
7: % of the protein sequence covered by the peptides identified.
8: number of peptides identified.
9: exponentially modified protein abundance index.
10: Subproteome compartment where the spot was identified. CW, cell wall; S, supernatant; T, total fraction.
11: predicted protein localization. C, cytoplasmic; S, secreted; PSE, predicted surface exposed.
12: reported as immunogen elsewhere.
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0Selected S. aureus immunoreactive proteins are widely
distributed among a panel of strains isolated from clinical
vs. subclinical ewe mastitis
In order to test the hypothesis that the seroproteomic
variations identified by SERPA on the two S. aureus iso-
lates were more widely distributed among isolates of a
specific host- and clinical-association, we screened an
additional 10 strains isolated from subclinical (n =5 )
and severe (i.e. clinical or gangrenous mastitis; n =5 )
cases of ewe mastitis for the presence of 2 selected pro-
teins by proteome analysis of supernatant samples (i.e.
2-DE and Coomassie blue staining). The O11 (severe
mastitis) protein selected was SspB, which belongs to a
proteolytic cascade where a metalloprotease aureolysin
(Aur) activates a serine protease zymogen proSspA,
which in turn activates the SspB cysteine protease [25].
SspB and the two other proteins, SspA and Aur of the
cascade, were recognized in O11 and yielded a very faint
signal in O46 (Figure 4A). SspB, one element of this
proteolytic cascade, was detected in the culture superna-
tant of strains isolated from clinical mastitis cases
whereas it was not found in the strains isolated from
subclinical mastitis (Figure 5A). The other protein tested
was O46_2740 gene product (with similarity to exfolia-
tive toxin family), which was specifically recognized in
O46 infections and did not yield any significant signal in
O11 infections (Figure 4B). When considering its pre-
sence in the culture supernatant of other S. aureus
strains isolated from clinical or subclinical mastitis
in ewes, we observed that it was only detected in the
subclinical strains (100%) whereas it was undetectable
in any of the strains isolated from clinical mastitis
(Figure 5B). These results show that at least these tested
proteins are differentially produced by S. aureus strains
isolated from clinical or subclinical mastitis cases.
Whether these differences are involved or not in the
onset and the acuteness of the subclinical vs. clinical
mastitis remains to be demonstrated.
Figure 2 Representative 2-DE gels and SERPA on supernatant fractions of S. aureus O11 (A) and S. aureus O46 (B). Supernatant samples
were prepared from stationary phase cultures of S. aureus strains grown anaerobically on iron-depleted RPMI. Preparative 2-DE gels were
Coomassie blue stained (left panel). Gels run in parallel were immunoblotted using the pools of sera obtained from group 1 (infected with O11)
animals (middle panels) or from group 2 (infected with O46) animals (right panels). Samples were run in parallel on 13 cm gels (pI 3-10; 14%
SDS-PAGE). Spots identified by MS/MS are labeled.
Le Maréchal et al. Veterinary Research 2011, 42:35
http://www.veterinaryresearch.org/content/42/1/35
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C
Figure 3 (A) Distribution of the immunoreactive proteins based on their experimentally observed (upper panel) or predicted (lower
panel) subcellular localization.( B) Distribution of the immunoreactive proteins based on their GO functional classes. (C) Venn diagram of
immunoreactive proteins defining the core and the accessory seroproteomes.
CB O11
SERPA
Group 1 (O11)
SspB
SspA
Aur
CB O46
O46-2740 
A
B
SERPA
Group 2 (O46)
SERPA
Group 1 (O11)
SERPA
Group 2 (O46)
Figure 4 SERPA of O11-specific (A) and O46-specific (B) immunoreactive proteins. Protein specific signals were zoomed in on Coomassie
blue stained gels (CB) and membranes revealed using sera obtained from animals infected with O11 (Group1) or O46 (Group 2). Aur, aureolysin;
SspA, glutamyl endopeptidase serine protease; SspB, staphopain B; O46-2740, gene product similar to exfoliative toxin family.
Le Maréchal et al. Veterinary Research 2011, 42:35
http://www.veterinaryresearch.org/content/42/1/35
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Two closely related S. aureus ovine strains reproducibly
induce distinct mastitis types in ewe and mouse models.
Contrarily to Escherichia coli mastitis, which severity is
mainly determined by host factors and not by the strains
features [26], it seems that in S. aureus, inter-strain var-
iations exist in terms of virulence potential. Such varia-
tions have been experimentally observed but the
involved staphylococcal factors have not been clearly
identified yet [27-29]. S. aureus content in virulence fac-
tors reportedly varies from strain to strain and this may
account for the large panel of symptoms encountered in
ruminant mastitis [30]. It was also shown that some ele-
ments of the core genome could account for host adap-
tation in S. aureus ruminant isolates [8]. Here, we show
that two closely related S. aureus strains are able to
induce dramatically different mastitis outcomes in ani-
mal model. The experimental mastitis induced in ewes
confirmed that strain O11, originally isolated from a
gangrenous mastitis, induced more severe infections
than strain O46 in ewes. To corroborate the finding of
the diversity of the clinical signs caused by O11 and
O46, the mouse model of mastitis was employed for
further investigation [31]. Despite variable susceptibility
to viral, fungal or bacterial infections among the differ-
ent mouse lines [32], the mouse model was validated as
an experimental approach to the study of bovine masti-
tis [33]. In this study, CD-1 mice infected with O11 or
O46 revealed diverse clinical signs and showed different
cytokine profiles: O46 induced higher IL-1b and TNF-a
levels in the mammary gland lysates and higher serum
levels of IL-1b and MCP-1. It has been shown that the
cytokines play a pivotal role in the development of the
mastitis [34-36]. Recent investigation revealed that the
proinflammatory cytokines, TNF-a and IL-1b, increased
the capacity of bovine endothelial cells to eliminate
intracellular S. aureus [37]. Endothelial cells may so
represent a functional and active defence barrier against
bacteria invasion of infected quarters. Higher synthesis
of proinflammatory cytokines in O46-infected mice
might thus reflect a higher anti-staphylococcal response
and may allow more effective elimination of strain O46.
Further investigation has to be conducted to confirm
this hypothesis. Altogether, our findings demonstrated
that these two well-characterized strains reproducibly
induce drastically different mastitis in terms of severity,
and will prove useful tools to gain further insights into
host-pathogen interactions.
Inventory of mastitis-associated core and accessory
seroproteomes in S. aureus reveals new mastitis-related
antigens
This study reports the application of SERPA to deter-
mine the core and accessory seroproteomes resulting
from experimental ewe mastitis induced by two different
S. aureus strains, isolated from a subclinical mastitis
(O46) and a gangrenous mastitis (O11). To determine
which proteins are recognized by the ewe immune sys-
tem during mastitis with different severity, experimental
infections were carried out on primiparous ewes using
clinical
clinical
subclinical
subclinical
Figure 5 Distribution of SspB (A) and O46-2740 product (B) in a panel of S. aureus strains isolated from clinical (a) and subclinical (b)
mastitis. Supernatant samples were prepared on stationary phase cultures of strains grown on iron-depleted RPMI. 2-DE gels were Coomassie
blue stained.
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SERPA profiles, this study allowed, for the first time, the
determination of core and accessory seroproteomes for
S. aureus in a mastitis context. Eighty nine proteins
were immunogenic in ewe mastitis implying they were
produced during the infection. Seventy four were found
in both seroproteome profiles and composed a core ser-
oproteome. Fifteen of them were found strain-specific
and composed the accessory seroproteome. Among the
74 proteins belonging to the core seroproteome, only 44
(59.5%) had already been reported to be immunogenic
in infections caused by S. aureus or other pathogens
(e.g. Bacillus anthracis, Staphylococcus epidermidis, Clos-
tridium perfringens, Schistosoma japonicum)( T a b l e2 ) .
Among these previously described antigens, only 30S
ribosomal S1 and LukM/LukF’-PV were previously
reported to be immunogenic in S. aureus bovine mastitis
[38,39]. These 44 proteins include most of the immunor-
eactive proteins categorized in Toxins-Haemolysins and
Virulence/Defence mechanisms. The remaining 30 pro-
teins (40.5%) are described for the first time as potential
staphylococcal antigens in a mastitis context and, to our
knowledge, were not described as immunogenic else-
where. In the accessory seroproteome, 8 out the 15 pro-
teins identified were already described as immunogenic
elsewhere whereas 7 of them (AhpF, Opp1A, VVbp,
Mqo, cysteine synthase and two hypothetical proteins)
are described as such for the first time (Table 2). A
majority of the proteins identified here are thus reported
as immunogenic for the first time in a mastitis context.
Furthermore, 37 out of 89 proteins of the total seropro-
teome (~42%) correspond to proteins described as sta-
phylococcal antigens for the first time whatever the
infection considered. Only four of these new antigens are
categorized in Toxins-Haemolysins and Virulence/
defense mechanisms. The other ones are mostly found in
Metabolism (n = 9), Information storage (n =7 ) ,a n d
Unknown function (n = 13). Only a few studies pre-
viously analyzed S. aureus proteome and all of them were
carried out on human isolates, which reportedly differ
from ruminant isolates [8,9,40] and the strains were
grown in laboratory culture conditions [4,41-46]. Here
we used two ovine isolates grown in culture conditions
mimicking the mastitis context [11]. These two criteria
might account for the abundance of new staphylococcal
antigens identified in this study.
Importance of secreted and exported proteins in
seroproteomic patterns
It is commonly assumed that surface exposed proteins
play a role in host-pathogen interactions and that,
because of their cellular localization, they are preferen-
tially recognized by the host immune system. In this
study, immunoreactive proteins were mainly identified
in protein samples prepared from supernatant and cell
wall fractions revealing, somehow, discrepancies
between experimental (gels of total, cell wall and super-
natant protein fractions) and theoretical localization (as
determined in silico). Indeed, among the 47 immunor-
eactive proteins that were predicted cytoplasmic, only
10 were experimentally found in the total fraction and
37 were found in supernatant or cell wall fractions
(Table 2). Such discrepancies were observed in other
studies as well [4,47,48]. Some proteins are multifunc-
tional and found both intra- and extracellularly. For
example, glyceraldehyde-3-phosphate dehydrogenase
[49] and enolase [50] were shown to be both cytoplas-
mic and surface exposed. In addition to their metabolic
role in the cytoplasm, they play a role as adhesins when
exposed on the bacterial surface. Furthermore, a new
mechanism of protein exportation in Gram positive bac-
teria was recently described and not included yet in pre-
diction tools for protein localization. It has actually been
demonstrated that S. aureus,l i k es o m eG r a mn e g a t i v e
bacteria, secretes membrane vesicles, which contained at
least 90 different proteins [51]. Twelve of the proteins
identified here were found in the vesicle-secreted pro-
teins identified by Lee et al. [51]. Whether the other
immunoreactive proteins identified here are secreted
through a membrane vesicle mechanism remains
undetermined.
The core seroproteome
Proteins belonging to the core seroproteome are immu-
nogenic regardless the severity of the induced mastitis.
These proteins are therefore good targets for the devel-
opment of new strategies against S. aureus mastitis.
Some of them have been tested as vaccine target to pre-
vent staphylococcal infections e.g., Enolase (Eno) [52],
IsdA (an iron-regulated cell wall-anchored protein) and
IsdB (a cell surface transferrin-binding protein) [53,54],
GapC/B protein (glyceraldehyde-3-phosphate dehydro-
genase) [55], Hla (alpha-hemolysin) [56]. These vaccines
seem at least to limit infection damage (by notably
decreasing mortality) but not to provide total effective
protection.
Well-known virulence factors, such as Hla, Hlb (beta-
hemolysin), SspA (V8 serine protease), ScpA (Staphopain
A), and Plc (phosphatidylinositol phosphodiesterase),
were identified here in a mastitis context and were pre-
viously identified as immunogenic in human infections
[4,57]. Hla and leukotoxins were reportedly produced in
vivo during mastitis [58] but to our knowledge this is the
first time that the other proteins listed in Table 2 are
shown to be produced in vivo during mastitis. These pro-
teins deserve more attention to test their role in the mas-
titis onset and to check their potential use as target for
vaccine development. Of note, we found 5 iron-related
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belonged to the core seroproteome) consistent with the
culture conditions (iron depletion) and with a role in the
physiologically important and difficult iron uptake in the
mastitis conditions.
The accessory seroproteome
Some proteins were shown to be specifically produced
by strain O11 or by strain O46 in infected ewes. None
of 12 proteins specifically produced by O11 in vivo had
previously been reported as produced during mastitis.
Their role in mastitis is thus unknown. Nevertheless
most of them have been described as immunogenic in
S. aureus infections in humans. Their function is mainly
linked to resistance to host immune response like for
IsdH [59], AhpF and TrxB, implied in oxidative stress
responses [60] that may confer O11 resistance to neu-
trophils and so be an advantage compared to O46, Sbi
that forms complexes with immunoglobulins Fc regions
[61], Aur and SspB. Aureolysin is essential for activation
of SspA [25], which in turn activates the SspB zymogen
[62]. Aur, SspA and SspB seemed to be more produced
in O11 than in O46. They can degrade conjunctive tis-
sue [63]. Aureolysin has been shown to be involved in
resistance to macrophage phagocytosis [64] and to sig-
nificantly contribute to the activation of the fibrinolytic
system [65]. It might thus reinforce the degradation of
extracellular matrix in the mammary gland and promote
bacterial spread and invasion. SspB can activate the che-
moattractant chemerin, which results in a local inflam-
mation of the tissue [66]. Moreover it induces the
depletion of functional phagocytes at the site of infec-
tion by blocking phagocytosis by neutrophils and inhi-
biting their chemotactic activity [67]. SspB may so take
part in the observed swelling of the mammary gland
observed during gangrenous mastitis. Moreover, it has
been shown that SspA and SspB play an important role
in virulence in a mouse abscess model [68]. Opp1A was
found to be produced by strain O11 in vivo. Opp pro-
teins seem to take part in virulence in several infection
models [69]. Although the role of Opp has not been
clearly demonstrated until now, Opp proteins have also
been reported to be involved in virulence in other Gram
positive pathogens such as group A streptococci [70],
Streptococcus agalactiae [71] or Listeria monocytogenes
[72]. A variant of von Willebrand factor-binding protein
gene has recently been located on the pathogenicity
island SaPIov2, characteristic of small ruminant isolates
[9]. Interestingly, besides being a coagulase, it is also an
activator of pro-thrombin [73] that is present in cow
milk [74]. Pro-thrombin activation in thrombin may
have a pro-inflammatory effect during mastitis and thus
take part in the symptoms observed in animals infected
by O11. Whether and how these proteins are involved
in the acuteness of the disease induced by O11 remains
unknown. O46 specifically produced 3 immunoreactive
proteins when compared to O11. IsaA has been
reported to be immunogenic in many S. aureus infec-
tions [3,52,57,75-77]. It presents autolytic activity and is
necessary for complete virulence [78] but its role in
mastitis is not known. Interestingly, a protein (encoded
by O46-2740) which shows similarity to exfoliative toxin
D (ETD) was found produced by O46 and not by O11.
Three amino-acids were shown to constitute the active
site common to all the exfoliative toxins [79]. These
amino-acids are present in O46_2740 gene (O46 strain)
product but one is missing in O11-0490 gene product.
The corresponding gene is not found in the recently
released sequence of ovine strain ED133 [9] although we
found its product in the exoproteome of 5 additional
S. aureus strains isolated from subclinical mastitis. ETD
is associated with cutaneous abscesses and furuncles
[80]. Interestingly this toxin is also produced by Coagu-
lase Negative Staphylococci species like Staphylococcus
hyicus, Staphylococcus pseudintermedius and Staphylo-
coccus chromogenes. CNS are highly prevalent in ovine
subclinical mastitis [81]. Whether this particular toxin is
specifically produced and plays a role during subclinical
mastitis remains to be tested. Altogether, proteins differ-
entially produced by O11 and O46 may be considered as
potential marker of gangrenous or subclinical mastitis
but this has still to be further demonstrated.
Conclusion
To the best of our knowledge, this study provides the
first comparative and comprehensive serological pro-
teome analysis in a mastitis context. The proteins identi-
fied are immunogenic in ewes implying that they are
also produced in the udder during infection. Many of
them are found immunogenic for the first time and a
g r e a tp r o p o r t i o nw a sf o u n di nt h es u p e r n a t a n ta n dc e l l
wall fractions even though they were predicted as cyto-
plasmic proteins. Whether or how these proteins are
really involved in the mastitis infection and or the sever-
ity of the mastitis remains to be elucidated. This study
provides a handful of interesting candidates for further
investigations on their potential use as new targets for
prophylactic or curative strategies such as vaccine or
drug target as some appear to be involved in important
virulence-associated functions (toxins, immune evasion,
iron uptake).
Additional material
Additional file 1: Table S1: Criteria used to define the acuteness of
mastitis symptoms.
Additional file 2: Figure S1: Dynamics of gangrenous mastitis onset in
ewes infected by S. aureus O11 (argyles) and O46 (squares).
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Page 16 of 20Additional file 3: Figure S2:( A) Intramammary growth of S. aureus
strain O11 and O46 in CD-1 mice. Populations are the mean values of S.
aureus counts in homogenates of 12 mice mammary gland. (B)
Temperature of infected mice 24h post-infusion. The mean value of the
groups of mice infected with S. aureus O11 or O46 is given. The dashed
line indicates the temperature of the animals at T0, before infection.
Asterisks indicate statistically significant values.
Additional file 4: Figure S3: Quantification of IL1b, IL6, TNF, KC and MCP-
1 in mammary gland lysates with BD
™™ Cytometric Bead Array. Cytokines
were quantified on homogenates of mammary glands infected by S. aureus
O11 or O46. Quantities are the mean values of 6 homogenates for each
group (O11 and O46) and are expressed in pg/20 μg of total protein.
Additional file 5: Figure S4: Quantification of IL1b, IL6, TNF, KC and
MCP-1 in serum with BD
™™ Cytometric Bead Array. Cytokines were
quantified in sera collected on 12 mice infected by S. aureus O11 (6 sera)
or O46 (6 sera). Quantities are the mean values of 6 sera for each group
(O11 and O46) and are expressed in pg/mL.
Additional file 6: Figure S5: Representative 2-DE gels and SERPA on cell
wall fraction (upper panels) and total proteins (lower panels) of S. aureus
O11. Supernatant samples were prepared from late exponential phase
cultures of S. aureus strains grown anaerobically on iron-depleted RPMI.
Preparative 2-DE gels were Coomassie blue stained (left panel). Gels run in
parallel were immunoblotted using the pools of sera obtained from group
1 (infected with O11) animals (middle panels) or from group 2 (infected
with O46) animals (right panels). Samples were run in parallel on 13 cm
gels (pI 4-7; 12% SDS-PAGE). Spots identified by MS/MS are labeled.
Additional file 7: Figure S6: Representative 2-DE gels and SERPA on
supernatant fractions of S. aureus O46 (upper panels) and S. aureus O11
(lower panels). Supernatant samples were prepared from late exponential
phase cultures of S. aureus strains grown aerobically on iron-depleted
RPMI. Preparative 2-DE gels were Coomassie blue stained (left panel).
Gels run in parallel were immunoblotted using the pools of sera
obtained from group 1 (infected with O11) animals (middle panels) or
from group 2 (infected with O46) animals (right panels). Samples were
run in parallel on 13 cm gels (pI 3-10; 12% SDS-PAGE). Spots identified
by MS/MS are labeled.
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